Deerfield Management Company, L.P. (Series C) Denali Therapeutics Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 May 15, 2023	SELL	$21.91 - $32.67 $4.49 Million - $6.7 Million	-205,011 Reduced 25.63%	594,989 $13.7 Million
Q4 2022 Feb 14, 2023	BUY	$26.28 - $33.92 $21 Million - $27.1 Million	800,000 New	800,000 $22.2 Million

Others Institutions Holding DNLI

# of Institutions

226

Shares Held

119M

Call Options Held

60.6K

Put Options Held

48.4K

Baillie Gifford & CO

13.3M
Shares

$311 Million
0.3% of portfolio
Black Rock Inc. New York, NY

13.2M
Shares

$307 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

11.2M
Shares

$261 Million
0.01% of portfolio
Wellington Management Group LLP Boston, MA

10.7M
Shares

$250 Million
0.06% of portfolio
Capital Research Global Investors Los Angeles, CA

7.91M
Shares

$184 Million
0.05% of portfolio

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.13B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account